Pharmaceuticals & Medical Products

Restoring value to biopharmaceutical R and 38D
article

Restoring value to biopharmaceutical R&D

August 2012—After years of seeing value destroyed by R&D excesses, biopharmaceutical companies can gain healthier returns—but only if they recognize several new imperatives.more

Editor's choice

How big data can revolutionize pharmaceutical R and D
article

How big data can revolutionize pharmaceutical R&D

April 2013—Pharmaceutical R&D suffers from declining success rates and a stagnant pipeline. Big data and the analytics that go with it could be a key element of the cure.more

  • includes:
    •  
A wake-up call for Big Pharma
article

A wake-up call for Big Pharma

December 2011—Lower profit margins suggest a need for new business models.more

Pharma manufacturing for a new era
article

Pharma manufacturing for a new era

August 2012—The sector can restore lost value by focusing intently on manufacturing innovation.more

Innovating in Chinas pharma market An interview with AstraZenecas head of R and 38D in Asia and emerging markets
interview

Innovating in China’s pharma market: An interview with AstraZeneca’s head of R&D in Asia and emerging markets

February 2012—The country may well foster new models of innovation, but success will require a long-term commitment and talent development.more

R and 38D in emerging markets A new approach for a new era
article

R&D in emerging markets: A new approach for a new era

February 2010—Gone is the time when R&D in developed markets could meet the pharmaceutical needs of emerging ones. A local presence is required.more

The road to positive R and 38D returns
article

The road to positive R&D returns

February 2010—Scientific innovation is not the only route to higher R&D productivity. Attention to the familiar management areas of cost, speed, and decision making can still reap rewards.more

Maximizing efficiency in pharma operations
article

Maximizing efficiency in pharma operations

April 2009—By matching the productivity of top drugmakers, average ones could enjoy labor and unit-cost savings worth five to six percentage points of earnings before interest and taxes.more

Capturing the Brazilian pharma opportunity
article

Capturing the Brazilian pharma opportunity

April 2012—Global pharma companies are missing a chance to serve Brazil’s increasingly prosperous and growing middle class.more

McKinsey conversations with global leaders Dan Vasella of Novartis
interview

McKinsey conversations with global leaders: Dan Vasella of Novartis

July 2009—The CEO and chairman of Novartis AG shares his personal approach to management and leadership and discusses health care reform, the economic downturn, and executive compensation.more

  • includes:
    •  
    •  
The microeconomics of personalized medicine
article

The microeconomics of personalized medicine

February 2010—Personalized medicine promises to increase the quality of clinical care and, in some cases, to decrease health care costs. The biggest hurdles are economic, not scientific.more

Engaging consumers to manage health care demand
article

Engaging consumers to manage health care demand

January 2010—Payors can help improve consumers’ health and reduce costs by providing information, choice, and incentives that encourage healthier lifestyles and value-conscious consumption of health care. more

The next wave of change for US health care payments
article

The next wave of change for US health care payments

May 2010—The development of an automated payment network would reduce bad debt, cut administrative costs, and save billions of dollars.more

The emerging market in health care innovation
article

The emerging market in health care innovation

May 2010—Innovators—some from developing nations—have found ways to deliver care effectively at significantly lower cost while increasing access and quality.more

Stay connected

About this content

The material on this page draws on the research and experience of McKinsey consultants and other sources. To learn more about our expertise, please visit the Healthcare Systems & Services Practice, Operations Practice, Pharmaceuticals & Medical Products Practice.